Literature DB >> 16682272

Negative signaling in Fc receptor complexes.

Marc Daëron1, Renaud Lesourne.   

Abstract

Cell activation results from the transient displacement of an active balance between positive and negative signaling. This displacement depends in part on the engagement of cell surface receptors by extracellular ligands. Among these are receptors for the Fc portion of immunoglobulins (FcRs). FcRs are widely expressed by cells of hematopoietic origin. When binding antibodies, FcRs provide these cells with immunoreceptors capable of triggering numerous biological responses in response to a specific antigen. FcR-dependent cell activation is regulated by negative signals which are generated together with positive signals within signalosomes that form upon FcR engagement. Many molecules involved in positive signaling, including the FcRbeta subunit, the src kinase lyn, the cytosolic adapter Grb2, and the transmembrane adapters LAT and NTAL, are indeed also involved in negative signaling. A major player in negative regulation of FcR signaling is the inositol 5-phosphatase SHIP1. Several layers of negative regulation operate sequentially as FcRs are engaged by extracellular ligands with an increasing valency. A background protein tyrosine phosphatase-dependent negative regulation maintains cells in a "resting" state. SHIP1-dependent negative regulation can be detected as soon as high-affinity FcRs are occupied by antibodies in the absence of antigen. It increases when activating FcRs are engaged by multivalent ligands and, further, when FcR aggregation increases, accounting for the bell-shaped dose-response curve observed in excess of ligand. Finally, F-actin skeleton-associated high-molecular weight SHIP1, recruited to phosphorylated ITIMs, concentrates in signaling complexes when activating FcRs are coengaged with inhibitory FcRs by immune complexes. Based on these data, activating and inhibitory FcRs could be used for new therapeutic approaches to immune disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682272     DOI: 10.1016/S0065-2776(05)89002-9

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  26 in total

Review 1.  The LAT story: a tale of cooperativity, coordination, and choreography.

Authors:  Lakshmi Balagopalan; Nathan P Coussens; Eilon Sherman; Lawrence E Samelson; Connie L Sommers
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-07-07       Impact factor: 10.005

Review 2.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

Review 3.  Signaling in lymphocyte activation.

Authors:  Doreen Cantrell
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-06-01       Impact factor: 10.005

Review 4.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

5.  LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection.

Authors:  Falk Nimmerjahn; Anja Lux
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-05       Impact factor: 11.205

Review 6.  Targeting B cells and autoantibodies in the therapy of autoimmune diseases.

Authors:  Daniela Kao; Anja Lux; Inessa Schwab; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

Review 7.  Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches.

Authors:  Falk Nimmerjahn
Journal:  J Clin Immunol       Date:  2016-03-08       Impact factor: 8.317

8.  Proteomic analysis of the SH2 domain-containing leukocyte protein of 76 kDa (SLP76) interactome in resting and activated primary mast cells [corrected].

Authors:  Yacine Bounab; Anne-Marie- Hesse; Bruno Iannascoli; Luca Grieco; Yohann Couté; Anna Niarakis; Romain Roncagalli; Eunkyung Lie; Kong-Peng Lam; Caroline Demangel; Denis Thieffry; Jérôme Garin; Bernard Malissen; Marc Daëron
Journal:  Mol Cell Proteomics       Date:  2013-07-02       Impact factor: 5.911

9.  IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

Authors:  Carol T Cady; Maree S Powell; Ronald J Harbeck; Patricia C Giclas; James R Murphy; Rohit K Katial; Richard W Weber; P Mark Hogarth; Syd Johnson; Ezio Bonvini; Scott Koenig; John C Cambier
Journal:  Immunol Lett       Date:  2009-12-30       Impact factor: 3.685

10.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.

Authors:  Nicole Schmitz; Klaus Dietmeier; Monika Bauer; Melanie Maudrich; Stefan Utzinger; Simone Muntwiler; Philippe Saudan; Martin F Bachmann
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.